Better Clinical Model Needed For Treament Of Heart Failure And Associated Depression
Main Category: Cardiovascular / CardiologyAlso Included In: Depression; Clinical Trials / Drug Trials
Article Date: 26 Jul 2007 - 7:00 PST
The National Institute of Mental Health (NIMH) has awarded researchers at the University of Pittsburgh School of Medicine a three-year, $500,000 grant to develop a novel intervention strategy for simultaneously treating congestive heart failure and major depression. The study is designed to obtain the necessary feasibility and clinical data required to plan a large-scale trial, which will compare the impact of a "blended" depression/heart failure care management programs vs. traditional heart failure care management program on cardiovascular morbidity and mortality, health-related quality of life, mood symptoms, health care costs and a variety of other outcomes of interest.
Heart failure affects 5 million Americans, with more than 550,000 newly diagnosed cases, 287,000 deaths and $30 billion in both direct and indirect costs each year. It also is the leading cause for hospitalization, and its five-year mortality rate following first hospital admission for heart failure exceeds that of most cancers.
Depression is present in approximately 20 to 50 percent of heart failure patients and compelling evidence links it to increased morbidity and mortality and reduced quality of life. Yet, although the University of Pittsburgh Medical Center (UPMC) and several other integrated health care delivery systems across the United States have implemented outpatient care management programs for heart failure, none routinely screen for and treat depression.
The study of the connections between mental health and cardiovascular disease is not new to the study's principal investigator, Bruce L. Rollman, M.D., M.P.H., associate professor of medicine and psychiatry, University of Pittsburgh School of Medicine. Since 2004, he and his co-principal study investigator, Charles F. Reynolds III, M.D., UPMC Professor of Geriatric Psychiatry, University of Pittsburgh School of Medicine, and their research team have been recruiting patients from several Pittsburgh-area hospitals, including UPMC Presbyterian and UPMC Passavant, into the first NIH-funded clinical trial titled, "Bypassing the Blues," designed to examine the impact of treating depressive symptoms following coronary artery bypass graft (CABG) surgery.
In this latest study, Drs. Rollman and Reynolds, with the help of their co-investigators Dennis McNamara, M.D., professor of medicine and director of UPMC Heart Failure Transplantation, and Rene Alvarez, M.D., associate professor of medicine and director of UPMC Heart Failure/Pulmonary Hypertension Network, will modify their "Bypassing the Blues" protocol for treating post-CABG depression. They will employ the UPMC outpatient guidelines for treating heart failure and then pilot their "blended" treatment strategy for treating depressed heart failure patients. They will recruit approximately 500 patients admitted for an acute episode of heart failure from UPMC Presbyterian, UPMC St. Margaret, UPMC Braddock and UPMC McKeesport hospitals, and then conduct follow-up telephone assessments at one, three and six months to estimate suitably sensitive and specific cut-off scores for treating depression by gender and severity of heart failure.
"The subject of depression and congestive heart failure has received little attention until recently. We need to look at these two conditions differently than in the past, as depression is seldom diagnosed and often untreated in patients with congestive heart failure," commented Dr. Rollman. "We also hope to learn through the cohort study how to better determine the severity of depressive symptoms that merit further attention from heart failure specialists."
"Cardiologists can help their patients if they are provided with the knowledge of depression's devastating effects on heart disease. Early studies have demonstrated that if patients are treated for depression after heart surgery or any invasive heart procedure, they are more likely to stick to their scheduled treatments and have a better, more positive outlook toward recovery," says Dr. McNamara.
"Depression is a complex disease with many symptoms similar to heart failure. If we can develop a better clinical model in recognizing and detecting depression, we hope to be able to gather enough data to support the need for a large-scale trial to test the effectiveness of a combined depression and heart failure treatment over the current standard of care for heart failure which does not address depression," added Dr. Reynolds.
###
CONTACT: Jocelyn Uhl Duffy
Other study co-investigators include Bea Herbeck Belnap and Wishwa N. Kapoor, M.D., of the department of medicine, University of Pittsburgh.
Source: Maureen McGaffin
University of Pittsburgh Schools of the Health Sciences
Visit our cardiovascular / cardiology section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/77685.php>
APA
http://www.medicalnewstoday.com/releases/77685.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
It Isn't Heart Failure That Causes Mental Changes
posted by Sharon I. Wells on 27 Jul 2007 at 1:14 pmAs a registered nurse AND a post heart attack patient, I can guarantee you that over 50 percent of mental changes in heart failure patients has to do with the medications the majority of them are given. Simply known as beta blockers. Mental changes are "noted" in the adverse affects but so far down on the list as to not be either included on pharmacy printouts or so far down as to make even the medical providers to believe it is a very rare occurrance.
I bid to say it isn't at all rare....some patients' symptoms from the affect of the beta blockers are so insidious and/or takes time to develop that it doesn't dawn on ANYONE that it's the medication, not process of disease.
I think it will be discovered soon that beta blockers are what is causing a major percent of Alzheimers. I can attest to that the beta blockers can imprison cognitive abilities, gives hallucinations so severe to promote inappropriate behavior. It just makes sense that if "amyloid beta plaques" are a "symptom" of "Alzheimer Disease" that a beta blocker would be the cause of the accumulations of amyloid beta plaques! DUG
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





